Takuro Kobori

Dr. Takuro Kobori

Osaka Ohtani University
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
Takuro KoboriTakuro Kobori
Takuro Kobori
SHShinichi Hamasaki
Shinichi Hamasaki
AKAtsuhiro Kitaura
Atsuhiro Kitaura
YYYui Yamazaki
Yui Yamazaki
TNTakashi Nishinaka
Takashi Nishinaka
HTHideo Takahashi
Hideo Takahashi
M2 macrophage promotes pathologic angiogenesis through a release of pro-angiogenic mediators or the direct cell-cell interaction with endothelium in the micromilieu of several chronic inflammatory diseases including rheumatoid arthritis and cancer where interleukin (IL)-18 also contributes to excessive angiogenesis. However, the detailed mechanism remains unclear. The aim of this study is to investigate the mechanism by which M2 macrophages in the micromilieu containing IL-18 induce excessive angiogenesis in the in vitro experimental model using mouse macrophage-like cell line, RAW264.7 cells, and mouse endothelial cell line, b.End5 cells. We discovered that IL-18 acts synergistically with IL-10 to amplify the production of macrophage-derived mediators like osteopontin and thrombin, yielding thrombin-cleaved form of osteopontin generation which acts through integrins α4/α9, thereby augmenting M2 polarization of macrophage with characteristics of increasing surface CD163 expression in association with morphological alteration. Furthermore, the results of visualizing temporal behavior and morphological alteration of macrophages during angiogenesis demonstrated that M2-like macrophages induced excessive angiogenesis through the direct cell-cell interaction with endothelial cells, possibly mediated by CD163.

30 January 2015 in Brain Structure and Function
Verified
Journal Article
Closed access
PDF file
ANAtsuko Niwa
Atsuko Niwa
MNMasahiro Nishibori
Masahiro Nishibori
SHShinichi Hamasaki
Shinichi Hamasaki
Takuro KoboriTakuro Kobori
Takuro Kobori
KLKeyue Liu
Keyue Liu
HTHideo Takahashi
Hideo Takahashi

1 May 2012 in European Journal of Pharmacology
Verified
Journal Article
Closed access
KNKazuo Nakamoto
Kazuo Nakamoto
SKShintaro Kawasaki
Shintaro Kawasaki
Takuro KoboriTakuro Kobori
Takuro Kobori
WFWakako Fujita-Hamabe
Wakako Fujita-Hamabe
HMHiroyuki Mizoguchi
Hiroyuki Mizoguchi
STShogo Tokuyama
Shogo Tokuyama

12 April 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SHShinichi Hamasaki
Shinichi Hamasaki
Takuro KoboriTakuro Kobori
Takuro Kobori
YYYui Yamazaki
Yui Yamazaki
AKAtsuhiro Kitaura
Atsuhiro Kitaura
ANAtsuko Niwa
Atsuko Niwa
HTHideo Takahashi
Hideo Takahashi
Advanced glycation end-products (AGEs), which comprise non-enzymatically glycosylated proteins, lipids, and nucleic acid amino groups, play an important role in several diseases and aging processes including angiopathy, renal failure, diabetic complications, and neurodegenerative diseases. Among AGE-associated phenotypes, toxic AGEs, glyceraldehyde-derived AGE-2, and glycolaldehyde-derived AGE-3 are involved in the pathogenesis of diabetic complications. In addition, macrophages are reported to remove extracellular AGEs from tissues via scavenger receptors, leading to the progression of atherosclerosis. In the present study, we found that AGE-2 and AGE-3 enhanced their own endocytic uptake by RAW264.7 mouse macrophage-like cells in a concentration-dependent manner. Furthermore, we demonstrated, for the first time, the morphology of phagocytic macrophages and the endocytosis of AGE particles. The toxic AGEs induced the expression of a scavenger receptor, CD204/scavenger receptors-1 class A (SR-A). Notably, an antibody against CD204 significantly prevented toxic AGE uptake. Moreover, an SR-A antagonistic ligand, fucoidan, also attenuated the AGE-2- and AGE-3-evoked uptake in a concentration-dependent manner. These results indicated that SR-A stimulation, at least in part, plays a role in AGE uptake.

1 January 2013 in Biological and Pharmaceutical Bulletin
Verified
Journal Article
Open access
PDF file
Takuro KoboriTakuro Kobori
Takuro Kobori
SHShinichi Harada
Shinichi Harada
KNKazuo Nakamoto
Kazuo Nakamoto
STShogo Tokuyama
Shogo Tokuyama
The maintenance of an appropriate serum concentration of a drug is known to be important for its pharmacological effects and the prevention of unexpected adverse effects. Functional alterations of drug transporters and drug-metabolizing enzymes may influence the serum concentration of drugs through changes in its pharmacokinetics and pharmacodynamics (PK/PD). There are many drug transporters expressed in the brain, liver, kidneys, and intestine including ATP-binding cassette (ABC) transporters and solute carriers (SLCs), which contribute to the systemic distribution of various drugs. Furthermore, the expression and function of P-glycoprotein (P-gp), one of the ABC transporters, is altered by environmental factors such as lifestyle and disease. In this review, we have focused on the influence of functional alterations in the intestinal P-gp on the PK/PD of drugs administered via the oral route under diabetic conditions. Altered expression patterns of intestinal P-gp observed under diabetic conditions exhibit pathological stage-dependency. Furthermore, many factors, such as serum glucose, insulin, nitric oxide, and cytokines, influence expression of intestinal P-gp. Finally, to design appropriate and individually targeted pharmacotherapy, it is necessary to consider the influence of alterations in the intestinal P-gp as well as drug metabolizing enzymes under diabetic conditions based on experimental results obtained from fundamental animal research.

1 March 2013 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
Takuro KoboriTakuro Kobori
Takuro Kobori
SHShinichi Harada
Shinichi Harada
KNKazuo Nakamoto
Kazuo Nakamoto
STShogo Tokuyama
Shogo Tokuyama